EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase IV)Open Access · CC BY 4.0

Faricimab for previously-treated eyes with neovascular age-related macular degeneration with inadequate response – 6-month interim analysis of the FURGGHORN study

Long T Phan, Jennifer Chin, Geoffrey K Broadhead, Thomas H Hong, Hemal Mehta, John H Chang, Samantha Fraser-Bell, Chui Ming Gemmy Cheung, Christopher Ziyu Sun, Alan P Luckie, Sanjeewa S Wickremasinghe, Gerald Liew und 4 weitere

Asia-Pacific Journal of Ophthalmology · 2026-03 · 15 (2) · 100299

DOI: 10.1016/j.apjo.2026.100299 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Asia-Pacific Journal of Ophthalmology, 2026-03. Verfasst von Long T Phan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cureos Research, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Wet Macular Degeneration. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wet Macular DegenerationAgedAged, 80 and overFemaleHumansMaleAngiogenesis InhibitorsFollow-Up StudiesIntravitreal InjectionsProspective StudiesRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityAntibodies, Bispecific

Stichwörter der Autor:innen

Age-related macular degenerationAng-2FaricimabIntravitreal injectionsVascular endothelial growth factor A

Substanzen

afliberceptAngiogenesis InhibitorsfaricimabRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAntibodies, Bispecific

Autor:innen und Institutionen

  • Cureos Research, Sydney, NSW, Australia.
  • Sydney Retina Clinic, Sydney, NSW, Australia; Strathfield Retina Clinic, Strathfield, NSW, Australia.
  • Eastwood Eye Specialists, Eastwood, NSW, Australia.
  • Sydney Retina Clinic, Sydney, NSW, Australia; Save Sight Institute, The University of Sydney, Sydney, NSW, Australia; Lane Cove Eye Surgery, Lane Cove, NSW, Australia; Department of Ophthalmology, Sydney Eye Hospital, S…
  • Singapore Eye Research Institute, Singapore National Eye Centre, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore.
  • EyeClinic Albury Wodonga, Albury, NSW, Australia.

Förderung

  • Roche

Zitieren

APA

Phan, L. T., Chin, J., Broadhead, G. K., Hong, T. H., Mehta, H., Chang, J. H., Fraser-Bell, S., Cheung, C. M. G., Sun, C. Z., Luckie, A. P., Wickremasinghe, S. S., Liew, G., Gilhotra, J. S., Simunovic, M. P., Verma, N., & Chang, A. A. (2026). Faricimab for previously-treated eyes with neovascular age-related macular degeneration with inadequate response – 6-month interim analysis of the FURGGHORN study. Asia-Pacific Journal of Ophthalmology, 15(2), 100299. https://doi.org/10.1016/j.apjo.2026.100299

Vancouver

Phan LT, Chin J, Broadhead GK, Hong TH, Mehta H, Chang JH, et al. Faricimab for previously-treated eyes with neovascular age-related macular degeneration with inadequate response – 6-month interim analysis of the FURGGHORN study. Asia-Pacific Journal of Ophthalmology. 2026;15(2):100299. doi:10.1016/j.apjo.2026.100299

BibTeX
@article{Phan2026,
  author = {Phan, Long T and Chin, Jennifer and Broadhead, Geoffrey K and Hong, Thomas H and Mehta, Hemal and Chang, John H and Fraser-Bell, Samantha and Cheung, Chui Ming Gemmy and Sun, Christopher Ziyu and Luckie, Alan P and Wickremasinghe, Sanjeewa S and Liew, Gerald and Gilhotra, Jagjit S and Simunovic, Matthew P and Verma, Nitin and Chang, Andrew A},
  title = {Faricimab for previously-treated eyes with neovascular age-related macular degeneration with inadequate response – 6-month interim analysis of the FURGGHORN study},
  journal = {Asia-Pacific Journal of Ophthalmology},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {100299},
  doi = {10.1016/j.apjo.2026.100299}
}
Kostenlos starten →